858 Therapeutics Stock Price, Funding, Valuation, Revenue

Jul 11, 2024 · See 858 Therapeutics funding rounds, investors, investments, exits and more. Evaluate their financials based on 858 Therapeutics's post-money valuation and revenue. ...

CouponFollow Extension

$50
OFF

858 Therapeutics Nabs $50M Round - San Diego Business Journal

6 days from now

Oct 14, 2024 · 858 Therapeutics’ headquarters are at One Alexandria on Merryfield Row in Torrey Pines. ... San Francisco’s IDEAYA Biosciences saw its stock price soar this summer following …

sdbj.com

$60
OFF

858 Therapeutics Launches With Proven Team And $60 Million …

6 days from now

Sep 21, 2021 · SAN DIEGO--(BUSINESS WIRE)--858 Therapeutics today exited stealth mode with a $60 million Series A financing led by founding investor Versant Ventures, with …

businesswire.com

$54
OFF

Gotham Therapeutics Stock Price, Funding, Valuation, Revenue ...

6 days from now

Sep 21, 2021 · Funding, Valuation & Revenue. Gotham Therapeutics has raised $54M over 3 rounds. Gotham Therapeutics's latest funding round was a Acquired for on September 21, …

cbinsights.com

$18.00
OFF

Stoke Therapeutics - Funding, Financials, Valuation & Investors

6 days from now

Their stock opened with $18.00 in its Jun 19, 2019 IPO. Stoke Therapeutics is funded by 9 investors. Alexandria Venture Investments and RA Capital Management are the most recent …

crunchbase.com

$178
OFF

Accent Therapeutics Stock Price, Funding, Valuation, Revenue ...

6 days from now

Jan 23, 2024 · Funding, Valuation & Revenue. Accent Therapeutics has raised $178M over 3 rounds. Accent Therapeutics's latest funding round was a Series C for $75M on January 23, …

cbinsights.com

$6
OFF

Cellics Therapeutics Company Profile 2024: Valuation, Funding ...

6 days from now

Pre-Clinical Trials. 1. Early Stage VC (Series A) 21-Apr-2017. $6M. $6M. Completed. Pre-Clinical Trials. To view Cellics Therapeutics’s complete valuation and funding history, request access ».

pitchbook.com

$142.58
OFF

Click Therapeutics Stock Price, Funding, Valuation, Revenue

6 days from now

Nov 6, 2023 · Click Therapeutics has raised $142.58M over 11 rounds. Click Therapeutics's latest funding round was a Debt - V for $20M on November 6, 2023. Date. Round. Amount. …

cbinsights.com

$250
OFF

Renova Therapeutics Company Profile 2024: Valuation, Funding ...

6 days from now

1. Grant. 02-Sep-2011. $250K. Completed. Startup. To view Renova Therapeutics’s complete valuation and funding history, request access ».

pitchbook.com

$15
OFF

Vivace Therapeutics Company Profile 2024: Valuation, Funding ...

6 days from now

Startup. 1. Early Stage VC (Series A) 20-Jan-2015. $15M. $15M. Completed. Startup. To view Vivace Therapeutics’s complete valuation and funding history, request access ».

pitchbook.com

$561
OFF

Biosplice Therapeutics Stock Price, Funding, Valuation, Revenue ...

6 days from now

Apr 15, 2021 · Funding, Valuation & Revenue. Biosplice Therapeutics has raised $561.5M over 6 rounds. Biosplice Therapeutics's latest funding round was a Series B for $120M on April 15, …

cbinsights.com

FAQs about 858 Therapeutics Stock Price, Funding, Valuation, Revenue Coupon?

What happened to 858 Therapeutics?

SAN DIEGO-- ( BUSINESS WIRE )--858 Therapeutics today exited stealth mode with a $60 million Series A financing led by founding investor Versant Ventures, with participation from NEA, Cormorant Asset Management and Logos Capital. ...

Where is 858 Therapeutics headquarters?

Where is 858 Therapeutics 's headquarters? 858 Therapeutics is located in San Diego, California, United States. Who invested in 858 Therapeutics? 858 Therapeutics has 4 investors including New Enterprise Associates and Cormorant Asset Management. ...

How many investors does biosplice therapeutics have?

Biosplice Therapeutics's deal structure is available for 1 funding round, including their Series A from August 06, 2018. Biosplice Therapeutics has 10 investors. SymBiosis invested in Biosplice Therapeutics's Series B funding round. Looking for a leg up on competitive, customer and technology insights? ...

How much is biosplice Therapeutics worth?

Biosplice Therapeutics's latest funding round was a Series B for $120M on April 15, 2021. Biosplice Therapeutics's valuation in August 2018 was $12,000M. Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. ...

What is a series a grant for 858?

The Series A proceeds will allow 858 to enter the clinic with its lead candidates that have potential to treat cancers that are resistant to current therapies. 858 is headquartered in San Diego and will maintain lab operations both in San Diego and New York City. ...

Why did 858 acquire Gotham Therapeutics?

To accelerate the development of its pipeline, 858 has acquired Gotham Therapeutics for undisclosed terms. Gotham is a pioneer in the field of RNA biology, translating novel biological discoveries from the lab of Samie Jaffrey, M.D., Ph.D., co-founder of Gotham and now an advisor to 858. ...